Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) have received a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $20.8333.

ADPT has been the subject of several recent research reports. Morgan Stanley lifted their price objective on Adaptive Biotechnologies from $18.00 to $20.00 and gave the stock an “equal weight” rating in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. TD Cowen increased their target price on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Guggenheim lifted their target price on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Finally, BTIG Research reissued a “buy” rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a research report on Wednesday, June 17th.

Adaptive Biotechnologies Stock Down 3.4%

Adaptive Biotechnologies stock traded down $0.74 during trading on Friday, hitting $21.06. The stock had a trading volume of 1,907,486 shares, compared to its average volume of 3,735,440. The stock’s 50 day moving average is $16.80 and its two-hundred day moving average is $16.03. Adaptive Biotechnologies has a 1 year low of $9.96 and a 1 year high of $22.80. The stock has a market cap of $3.37 billion, a price-to-earnings ratio of -63.82 and a beta of 2.07.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The business had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. During the same period last year, the business posted ($0.20) earnings per share. The business’s revenue for the quarter was up 35.1% on a year-over-year basis. As a group, equities research analysts anticipate that Adaptive Biotechnologies will post -0.47 EPS for the current fiscal year.

Insider Buying and Selling at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Sharon Benzeno sold 154,768 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $21.14, for a total transaction of $3,271,795.52. Following the sale, the insider owned 221,278 shares in the company, valued at $4,677,816.92. This represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harlan S. Robins sold 386,240 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $22.01, for a total value of $8,501,142.40. Following the completion of the transaction, the insider directly owned 1,019,658 shares of the company’s stock, valued at $22,442,672.58. The trade was a 27.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 958,665 shares of company stock worth $19,109,191. 5.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of institutional investors and hedge funds have recently modified their holdings of ADPT. Caitong International Asset Management Co. Ltd bought a new position in Adaptive Biotechnologies in the 4th quarter valued at $28,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares in the last quarter. Assetmark Inc. increased its position in shares of Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after purchasing an additional 2,708 shares during the last quarter. T. Rowe Price Investment Management Inc. purchased a new position in shares of Adaptive Biotechnologies during the 4th quarter valued at about $51,000. Finally, Strive Financial Group LLC bought a new stake in Adaptive Biotechnologies in the 4th quarter worth approximately $52,000. 99.17% of the stock is owned by hedge funds and other institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.